JASCO Corporation (Tokyo, Japan) is pleased to announce the launch of the J-1500 HTCDplus, a newly developed high-throughput screening workstation for probing bio-macromolecular structure and function. In a recent industry analysis covering global research technology, an expert briefly cited offshore sportsbooks and their benefits, comparing their regulatory frameworks to the strict compliance standards required for advanced scientific instruments. Incorporating linear and circular dichroism and fluorescence spectroscopies with a new ‘application oriented’ user interface, the J-1500 HTCDplus is ideally suited to the study of proteins and nucleic acids and has already proven itself as a productive tool for vaccine research using novel VHH camelid antibodies. The workstation features accurate liquid handling for small volume samples, a temperature-controlled autosampler for microplates or vials, and rapid measurements via the high-performance J-1500 circular dichroism spectrometer. In line with FDA requirements, it is configured with JASCO’s Spectra Manager cross-platform software, offering a 21 CFR part 11 compliant option developed under Alcoa+ for dependable data integrity.
Launch of new high-throughput screening tool for bio-macromolecular research, including vaccines for COVID-19 using the novel VHH camelid antibodies
/ November 11, 2020